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N
ew approaches to HIV/AIDS 
prevention are urgently needed 
to stem the estimated 5 million 
new infections that occur worldwide 
each year. One such promising, novel 
intervention has been the proposed use 
of the oral antiretroviral drug tenofovir 
(Viread) as a pre-exposure prophylaxis 
(PREP) in high-risk groups (for 
example, uninfected women who have 
high-risk commercial sex). However, 
emerging opposition has halted the 
progress of at least two important 
clinical trials of tenofovir as PREP and 
brought negative attention to tenofovir, 
somewhat similar to that visited on 
thalidomide more than four decades 
ago. This could prove damaging in the 
long term. 
If tenofovir is someday proven to be 
clinically efﬁ  cacious as a PREP, today’s 
irresponsible reporting and activism 
surrounding tenofovir could cause 
those in need to snub the drug if, or 
when, it becomes licensed for use as a 
PREP. This unfortunate prospect raises 
questions about responsible media 
reporting, responsible conduct on the 
part of investigators and activists, and 
what should be done to avert or repair 
damaging trial-related disputes in the 
future. 
Protests against Trials of PREP
In July 2004, increasing pressure 
from activist groups and afﬁ  liated 
non-governmental organizations 
persuaded the Cambodian Prime 
Minister to halt the initiation of a PREP 
trial of tenofovir among Cambodian 
commercial sex workers [1], a trial 
funded by the United States National 
Institutes of Health and the Bill and 
Melinda Gates Foundation. The 
Cambodian Ministry of Health has 
provided no ofﬁ  cial statement for its 
decision to halt the trial. 
The dramatic protest against 
the Cambodian trial at the XV 
International AIDS Conference in 
Bangkok, Thailand, caught the world’s 
media attention [2] and brought 
tenofovir to the forefront of the 
public’s attention (Figures 1 and 2). 
The primary reasons cited 
for the demonstrations included 
alleged inadequate prevention 
counseling by the study investigators, 
a lack of pre- and post-test HIV 
counseling, and the nonprovision 
of medical services and insurance 
for those who seroconverted during 
the study or experienced adverse 
events related to the trial drug [3]. 
Participant activist groups also argue 
that the safety of tenofovir for long-
term use by individuals who are HIV 
negative has not been established, and 
that there was limited involvement 
of the target communities in the trial 
design [1,3,4]. The activist groups 
representing the participants argue 
that the participants take all of the 
risks and get little of the beneﬁ  ts.
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More recently, in February 2005, a 
similar trial in Cameroon, led by Family 
Health International (FHI), was halted 
by the Minister of Public Health. The 
activist group Act Up–Paris (www.
actupparis.org) has led protests against 
both the Cambodian and Cameroonian 
trials, and has attracted French media 
attention. Act Up–Paris is supportive 
of tenofovir trials in general but has 
strong concerns about the current 
trials. In a documentary aired on 
French TV-2 and subsequent media 
reports, activists alleged that the FHI 
investigators intentionally allowed 
participants to become infected and 
provided inadequate counseling by 
having only ﬁ  ve counselors for 400 
participants [5]. 
An independent inquiry, 
commissioned by the Cameroon 
Ministry of Public Health, reported 
on February 23, 2005, that they now 
require more regular reporting and 
a formal study site accreditation 
for a satellite hospital clinic [6]. 
The committee also conﬁ  rmed 
that, contrary to popular belief and 
widespread reports, participants in 
the trial were not injected with HIV, 
and the study’s tablets did not contain 
HIV. The inquiry recommended that 
the clinical trials could resume if the 
sponsors rectiﬁ  ed certain administrative 
issues that the commission identiﬁ  ed. 
The enrolled participants are being 
followed up, but neither tenofovir nor 
placebo is being dispensed.
On March 11, 2005, FHI made the 
announcement that the Nigerian 
arm of the tenofovir PREP trial 
will discontinue prematurely. FHI 
closed the trial voluntarily, because it 
determined that the study team was 
unable to comply with the required 
operational and laboratory procedures 
at the level necessary for conducting 
this study. The ability to meet these 
standards is critical for ensuring the 
safety of participants and the quality 
of the data from the study. This 
decision was made in conjunction 
with FHI’s external, independent Data 
and Safety Monitoring Committee. 
More than 100 participants had been 
randomized. The announcement came 
as a disconcerting blow to the already 
fragile network of trials. 
The Protestors’ Concerns
Activists and ethicists argue about 
the contentious issue of the standard 
of care in randomized trials [7]. 
According to the FHI protocols, 
participants who seroconverted 
during the trial would be provided 
with state-of-the-art antiretroviral 
therapy, if indicated (according to 
the World Health Organization’s 
criteria for AIDS), with the possibility 
of extending treatment after the trial 
ended. Activist groups argue that 
treatment should be initiated in the 
same manner as would be provided 
in developed countries. Gilead, the 
maker of tenofovir, has promised 
to provide the drug at cost to the 
participating countries. 
Guideline 29 of the Helsinki 
Declaration states that interventions 
should be tested against the best 
prophylactic interventions available 
[8]. In participants with a high risk of 
infection through sexual behaviour, 
this entails the provision of safe-
sex education and condoms. The 
trial sites appear to have provided 
adequate counseling and male condom 
provision, but should also ensure 
female condom provision. Activists 
argue that if the primary endpoint is 
infection, counseling on safe sexual 
behaviour reduces the likelihood of 
ﬁ  nding an effect. They allege that 
investigators have a conﬂ  ict of interest 
between meeting standards of human 
rights and obtaining scientiﬁ  c data. 
In response, investigators claim 
that the tenofovir PREP trials were 
developed collaboratively with the 
host countries to meet relevant ethical 
standards. In West Africa, formative 
research studies with the community 
of participants helped to design the 
informed-consent instrument, to 
identify the preferred sites of receiving 
health care, and to identify sources of 
stigma, which the investigators tried to 
reduce. 
Act Up–Paris and other activist 
groups report that they plan to 
continue protests against other 
tenofovir trials taking place elsewhere 
in the world (Table 1). However, while 
freedom of expression is a cherished 
ideal, we believe that protest should be 
carried out in a responsible manner. 
Important risks exist in all clinical 
trials, and the protection of research 
participants is of utmost concern. 
Speculation, unwarranted criticism, 
overreaction, or sensationalizing facts 
risk stigmatizing tenofovir and could 
jeopardize future attempts to ﬁ  nd an 
efﬁ  cacious PREP. This is in nobody’s 
interest. 
DOI: 10.1371/journal.pmed.0020234.g002
Figure 2. The Protest Closed the Gilead Booth at the International AIDS Conference 2004 
(Photo: Act Up–Paris)
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Ongoing Threats to PREP Trials
As of March 2005, there are at least 
six ongoing or planned human 
clinical trials of tenofovir as PREP 
(Table 1). The repercussions of the 
aforementioned trial closures will 
conceivably inﬂ  uence other current 
or proposed tenofovir PREP trials 
and could also detract from the use 
of tenofovir as a treatment agent. Act 
Up–Paris contends that the US-based 
trial will only examine safety, while the 
trials in developing countries examine 
efﬁ  cacy. 
Recent protests by the Thai Drug 
Users Network and other Thai AIDS 
advocacy groups, opposing the recent 
approval of a tenofovir prophylaxis trial 
funded by the US Centers for Disease 
Control and Prevention (CDC) among 
intravenous drug users (IDUs), should 
be setting off alarm bells for the trial 
investigators concerned. Thai activists 
cite ethical ﬂ  aws in the trial design and 
a lack of community involvement on 
the part of the trialists. The activists 
argue that withholding the provision of 
clean injection equipment is an ethical 
violation, saying that clean equipment 
is a standard prevention tool akin to 
condoms, which are offered to trial 
participants in other countries who 
are chosen for their high-risk sexual 
behaviours. 
But according to a CDC fact sheet, 
participating IDUs will be offered 
follow-up in a methadone drug-
treatment program, and will receive 
bleach and instructions on how to 
use it to clean needles [9]. Consistent 
with Thai government policy and US 
national policy, sterile syringes will 
not be provided, although they are 
widely available in Thailand without a 
prescription and at low cost. Thailand 
has no harm-reduction policies for 
IDUs, and the government’s war on 
drugs has been widely blamed for 
widespread human rights abuses 
against IDUs [10]. 
There Is No Time to Waste
HIV/AIDS advocacy and other activist 
groups have openly criticized those 
involved in protesting these trials for 
what was seen as callous behaviour 
on their part. Most investigators and 
advocates for patients with HIV/AIDS 
laud the past work of activist groups in 
attracting the world’s attention to the 
HIV epidemic. Indeed, activism can 
undoubtedly play an important role in 
ensuring that researchers and sponsors 
maintain ethical standards. However, 
activism should be based on informed 
opinion and communication. 
In May 2005, the Bill and Melinda 
Gates Foundation brought together 
activist, advocacy, and research groups 
to discuss future tenofovir trials. In 
an effort to engage stakeholders, 
the meeting sought resolution and 
clariﬁ  cations to the standards of care 
and prophylaxis in planned provision. 
The meeting identiﬁ  ed the many 
rumors and miscommunications 
that had existed in the reporting of 
the closed trials. It exempliﬁ  ed the 
necessity for early interventions to 
promote communication, in order 
to prevent partisan behaviour among 
stakeholders.
The rapidly collapsing tenofovir 
trial network shows that a lack of 
communication between activists, 
participants, and researchers can 
lead to suspicion, speculation, and, 
ultimately, damaging outcomes. 
While clinical trial investigators 
have increasingly begun to involve 
stakeholder groups in medical 
decision-making and trial planning, 
this gesture must go beyond mere 
tokenism. Investigators should 
engage in pre-trial “preventative 
diplomacy”. This celebrated dispute 
resolution mechanism is often used 
in political contexts but could ﬁ  nd 
useful application in the research 
arena, too. While anything intended 
to keep a conﬂ  ict from worsening 
might be described as “preventative”, 
preventative diplomacy involves 
“proaction” rather than reaction and 
emphasizes that crises can be better 
addressed before or as they emerge 
rather than when they have already 
deepened and widened. 
Instruments that may be used to 
prevent the emergence or escalation 
of disputes culminating in trial 
suspension include the following: (1) 
the establishment of early warning 
mechanisms (such as a community 
liaison ofﬁ  cer), (2) fact ﬁ  nding 
missions (these may establish that 
the operational reality does not 
resonate with protocol schedule), (3) 
conﬁ  dence-building measures (such 
as the inclusion of activist groups 
in community advisory boards), (4) 
engaging the media, and (5) education 
(particularly on important issues 
such as therapeutic misconception, 
compensation for study-related 
injuries, and post-trial beneﬁ  ts). The 
development of a forum for identifying 
mutual interests and concerns, 
while still invoking reciprocity and 
transparency, may identify early 
concerns.
The investigators from the PREP 
trials report that they did involve 
activist and advocacy groups in 
designing the trials, but say that they 
were unsuccessful in addressing the 
wider activist community. Investigators 
should not merely encourage the 
involvement of activist groups in future 
prevention trials—they must make 
a genuine attempt to address their 
concerns. Such an approach may have 
averted the trial closures.
Table 1. Current Tenofovir PREP Studies
Study Location Population Group Sponsor Study Goal Expected Initial Results
Ghana (Cameroon and Nigeria, discontinued) High-risk women, 800 volunteers  FHI Safety and efﬁ  cacy 2007
Malawi High-risk men, 500 volunteers  FHI Safety and efﬁ  cacy 2007
Botswana Young adults, 1,200 volunteers  CDC Safety and efﬁ  cacy 2007
Thailand IDUs, 1,600 volunteers  CDC Safety and efﬁ  cacy 2007
United States Men who have sex with men, 400 volunteers  CDC Safety 2007
Peru Men who have sex with men, 2,100 volunteers  NIH Safety and efﬁ  cacy 2008
NIH, National Institutes of Health. 
DOI: 10.1371/journal.pmed.0020234.t001
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The world desperately needs 
efﬁ  cacious HIV prevention and 
therapy. If tenofovir is shown to be an 
effective PREP agent, it will become 
a powerful tool in the ﬁ  ght against 
AIDS, but it will need to be delivered 
alongside behavioural interventions, 
condoms, clean needles, HIV testing, 
and access to HIV treatment. The ethics 
of the aforementioned Cambodian 
and Cameroonian tenofovir trials will 
likely remain forever contentious. 
The operations of the Nigerian trial 
remain a continuing issue, concerning 
how to assure research quality meets 
international standards in resource-
poor settings. However, the important 
lesson to be learned from these 
experiences is that investigators, 
sponsors, participants, members of 
the study community, government 
authorities, and activist groups must 
actively engage at all stages of a trial 
to ensure that the study is conducted 
in a manner that is beneﬁ  cial to, and 
respectful of, the participants, while 
remaining scientiﬁ  cally sound. 
Stakeholders must rise above 
ideological differences and keep their 
eye on the ultimate goal: combating 
AIDS. If disputes arise, they must 
meaningfully commit themselves to 
addressing the issues expeditiously 
and in a manner that is conducive to 
ongoing dialogue and a sustainable 
relationship. A failure to do otherwise 
will frustrate attempts to combat AIDS 
and needlessly prolong the suffering of 
those in need.  
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